Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

High BRAF V600 Mutation Level Associated with Worse Outcome in Metastatic Melanoma Patients Receiving BRAF and MEK Inhibitors.

Acta dermato-venereologica - 7 Nov 2024

Fizazi Ariane, Serrand Chris, Evrard Alexandre, Bergeret Blanche, Stoebner Pierre-Emmanuel, Marque Myriam

Abstract excerpt

The prognostic value of BRAF V600 mutation level on clinical outcomes in patients with BRAF V600-mutated metastatic melanoma treated with BRAF and MEK inhibitors remains uncertain. The association was retrospectively analysed between BRAF V600 mutation level (defined as the ratio of the quantification of the BRAF V600 allele to the percentage of tumoral cells in the sample analysed) and progression-free and...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Biomarkers, Tumor
Share to Melanoma

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Progression-Free Survival

Share to Protein Kinase Inhibitors

Share to Proto-Oncogene Proteins B-raf

Share to Skin Neoplasms

Share to Time Factors

Share to Treatment Outcome

Source

Open in PubMed Open full text

Identifiers

PMID: 39508497
DOI: 10.2340/actadv.v104.40913
PMCID: PMC11558860

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 4 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

High BRAF V600 Mutation Level Associated with Worse Outcome in Metastatic Melanoma Patients Receiving BRAF and MEK Inhibitors.PMID 39508497Read ↗

BRAF(V600) mutation levels predict response to vemurafenib in metastatic melanoma.Semantic proximity Read ↗

Non-V600E/K BRAF Mutations in Metastatic Melanoma: Molecular Description, Frequency, and Effectiveness of Targeted Therapy in a Large National Cohort.Semantic proximity Read ↗

High BRAF variant allele frequencies are associated with distinct pathological features and responsiveness to target therapy in melanoma patients.Semantic proximity Read ↗

BRAF mutational status as a prognostic marker for survival in malignant melanoma: a systematic review and meta-analysis.Semantic proximity Read ↗

BRAFV600 variant allele frequency predicts outcome in metastatic melanoma patients treated with BRAF and MEK inhibitors.Semantic proximity Read ↗

Response to MAPK pathway inhibitors in BRAF V600M-mutated metastatic melanoma.Semantic proximity Read ↗

Prognostic value of BRAF(V⁶⁰⁰) mutations in melanoma patients after resection of metastatic lymph nodes.Semantic proximity Read ↗

Prognostic relevance of lactate dehydrogenase and serum S100 levels in stage IV melanoma with known BRAF mutation status.Semantic proximity Read ↗

Targeted Therapy in Advanced Melanoma With Rare BRAF MutationsSemantic proximity Read ↗

BRAF Mutations in Metastatic Malignant MelanomaSemantic proximity Read ↗

Predictive and prognostic roles of BRAF mutation in patients with metastatic colorectal cancer treated with anti-epidermal growth factor receptor monoclonal antibodies: a meta-analysis.Semantic proximity Read ↗

Survival according to BRAF-V600 tumor mutations--an analysis of 437 patients with primary melanoma.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.